natgillin/translations-raw huggingface dataset:
The fractions of interest were combined and the solvent removed at reduced pressure. 
Poželjne frakcije se spoje 1 otapalo se ukloni uz smanjeni tlak.
Preferably, said tablets consist of a coated core, with the core containing racecadotril. The tablet has a weight of between 350 and 600 mg. 
Tableta racekadotrila koja sadrži prevučenu jezgru, te navedena jezgra sadrži racekadotril, naznačena time da jezgra sadrži, težinske udjele: -
The multipurpose airway device as claimed in any one of the preceding claims, in which the chosen elastomeric material of the plate has a high elastic limit but does not display plasticity in its working range, so that the lips of the patient function as a purse string largely because of the bulk of the orbicularis oris muscle even when it is relaxed and not contracting, whereby the rim around the perimeter of the plate resists distortion and when in place in the vestibule of the mouth sits outside the orbicularis oris muscle and especially at the corners of the mouth and so retains the plate even during positive pressure breaths and the plate is further supported in position in the vestibule of the mouth between the lips and cheeks, gums and teeth of the patient by the airway device traversing and firmly gripped in the central aperture of the plate. 
Višenamjenski uređaj za disanje sukladno bilo kojem prethodnom zahtjevu, u kojem je izabrani elastomerski materijal vrlo elastičan, ali prilikom upotrebe ne iskazuje plastičnost, pa se usne pacijenta ponašaju kao kesa, 1 to većinom radi pritiska sljepoočnog mišića čak 1 kad je isti opušten, a ne stegnut, pri čemu se obrub pločice ne izobličava, a kad je na svom mjestu u usnoj šupljini, nalazi se u uglovima usta i izvan je dosega sljepoočnog mišića te tako drži pločicu na mjestu čak 1 tijekom disanja uz pozitivni tlak, pločica se nadalje drži na mjestu u usnoj šupljini između usana i obraza, desnih i zubi pacijenta pomoću uređaja za disanje, koji prolazi 1 čvrsto je stisnut u središnjem otvoru pločice.
represents C1-C4alkylene, —C(═O)— or a group —C2H4S— being linked to the adjacent NR5-group via the carbon atom; 
A4 predstavlja C,-C,alkilen, ili skupinu koji su vezani na susjednu skupinu NR5- preko atoma ugljika;
The 42-0-(glycosylcarbonyl) rapamycin compounds of the present invention are prepared in such a way as to retain the trans configuration of the 41- and 42-substituents. 
42-O-(glikozilkarbonil)rapamicinski spojevi ovog izuma pripremaju se na takav način da se zadrži trans-konfiguracija 41- i 42-supstituenata.
A pyrazolo pyridine derivative according to any one of claims 1 to 12 for the treatment of a disease or condition selected from cardiovascular disorders, respiratory disorders, metabolism disorders, skin disorders, bone disorders, neuroinflammatory and/or neurodegenerative disorders, kidney diseases, reproduction disorders, diseases affecting the eye and/or the lens and/or conditions affecting the inner ear, inflammatory disorders, liver diseases, pain, cancers, allergic disorders, traumatisms, septic, hemorrhagic and anaphylactic shock, diseases or disorders of the gastrointestinal system, angiogenesis, angiogenesis-dependent conditions and other diseases and/or disorders associated with Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). 
Derivat pirazol piridina prema bilo kom patentnom zahtjevu od 1 do 12, za upotrebu u tretmanu bolesti ili stanja izabranih iz grupe koju čine kardiovaskularni poremećaji, respiratorni poremećaji, poremećaji metabolizma, poremećaji na koži, poremećaji u kostima, neuroupalni i/ili neurodegenerativni poremećaji, oboljenja bubrega, poremećaji u reprodukciji, bolesti koje utječu na oko i/ili leću oka i/ili stanja koja utječu na unutrašnje uho, upalni poremećaji, bolesti jetre, bol, rak, alergijski poremećaji, ozlijede, septički, hemoragični 1 anafilaktički šok, bolesti i poremećaji gastrointestinalnog sistema, angiogeneza, stanja koja su uvjetovana angiogenezom, kao i druga oboljenja i/ili poremećaji koje karakterizira izmijenjena aktivnost ili funkcija oksidaze nikotinamid adenin dinukleotid fosfata (NADPH oksidaze).
The anti-IL-5 antibody for the use according to claim 1, wherein said mean maximum plasma concentration is in the range of 12.1 ± 2.4 µg/mL to 278 ±29 µg/mL or wherein said AUC(0-inf) is in the range of 207 ±34 µg×day/mL to 4361 ± 168 µg×day/mL. 
Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što je navedena srednja najveća koncentracija u plazmi u rasponu od 12,1 ± 2,4 µg/ml do 278 629 µg/ml i/ili što je navedeni AUC(0-∞) u rasponu od 207 634 µg×dan/ml do 4361 ± 168 µg×dan/ml.
The compound according to claim 1 for use in treatment of an allergic disease, systemic mastocytosis, a disorder accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, a diseases accompanied by itch, a disease which is generated secondarily as a result of behavior accompanied by itch, inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, or ulcerative colitis. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u liječenju alergijske bolesti, sistemske = mastocitoze, poremećaja praćenog sistemskom aktivacijom mastocita, anafilaktičkog šoka, bronhokonstrikcije, bronhitisa, koprivnjače, ekcema, bolesti praćenih svrbežom, bolesti koja je sekundarna posljedica ponašanja praćenog svrbežom, upale, kroničnih opstruktivnih plućnih bolesti, ishemično-reperfuzijske ozljede, cerebrovaskularnog akcidenta, kroničnog reumatoidnog artritisa, pleurizma, ili ulceroznog kolitisa.
An oligonucleotide equivalent according to claim 4, wherein the nucleotide analogue has a modified base. 
Besmisleni oligonukleotid u skladu s patentnim zahtjevom 4, pri čemu analog nukleotida ima modificiranu bazu i/ili modificiranu unutarnukleozidnu vezu.
The first therapeutic agent is represented by Formula (I) or a pharmaceutically acceptable salt thereof; and the second therapeutic agent is effective for the treatment of Gaucher disease. Another embodiment is the hemitartrate salt of the compound represented by formula I, wherein at least 70% by weight of the salt is crystalline, or wherein the salt is an amorphous salt, for use in a method of treating a subject with Fabry disease. 
: ili njegova farmaceutski prihvatljiva sol, za proizvodnju lijeka naznačeno time da je za upotrebu za liječenje Gaucherove bolesti, pri čemu navedeno liječenje obuhvaća davanje učinkovite količine prvog terapijskog sredstva u kombinaciji s učinkovitom količinom drugog terapijskog sredstva koje je korisno za liječenje Gaucherove bolesti.
A peptide mixture according to claim 5, for use in inducing an immune response against cancer, wherein the cancer is colorectal, lung and/or pancreatic cancer. 
Peptidna smjesa u skladu sa bilo kojim od patentnih zahtjeva 1-3, smjesa T stanica u skladu sa patentnim zahtjevom 4 ili farmaceutska kompozicija u skladu sa patentnim zahtjevom 5, za primjenu u profilaksi i/ili
A cell culture system comprising cells which contain a recombinant nucleic acid coding for a vitamin K reductase complex subunit 1 (VKORC1) and a recombinant nucleic acid coding for a vitamin K dependent (VKD) protein, wherein both the recombinant VKORC1 and the VKD protein are expressed in said cells, and wherein the secretion rate of the recombinantly expressed VKD protein is substantially increased when compared to the expression of the rVKD protein in a host organism which does not co-express rVKORC1. 
Sustav stanične kulture, naznačen time, da obuhvaća stanice koje sadrže jednu rekombinantnu nukleinsku kiselinu, koja kodira za kompleksnu podjedinicu 1 reduktaze vitamina K (VKORCI) 1 jednu rekombinantnu nukleinsku kiselinu, koja kodira za vitamin K-ovisan protein (VKD), pri čemu su i rekombinantna VKORCI kao i rekombinantni VKD-protein eksprimirani u spomenutim stanicama, te se pritom količina sekrecije rekombinantno eksprimiranog VKD-proteina uglavnom povećava u usporedbi s ekspresijom rVKD-proteina u organizmu domaćina, koji ne ko-eksprimira TVKORC1.
Process according to claim 9, wherein the reaction is carried out in a mixture of organic solvent and water, particularly in a ratio of 10:1 to 1:10, preferably 8:1 to 1:3, more preferably 5:1 to 1:1, most preferably 4:1 to 2:1, wherein the organic solvent is preferably selected from acetonitrile, acetone, methanol, ethanol, isopropanol and mixtures thereof. 
Postupak prema zahtjevu 9, naznačen time, da se reakcija provodi u mješavini organskog otapala i vode, posebno u omjeru od 10:1 do 1:10, poželjno od 8:1 do 1:3, još bolje od 5:1 do 1:1, najbolje od 4:1 do 2:1, pri čemu je organsko otapalo poželjno odabrano od acetonitrila, acetona, metanola, etanola, izopropanolainjihovih mješavina.
Accordingly, three rinsing phases allow reaching LAL, TOC, Bio Burden and pH that are conform to those required for starting a new run with the system. 
HR P20080103 T3 tomu, prva tri ispiranja omogućavaju dostizanje vrijednosti LAL-a, TOC-a, biološkog opterećenja i pH koje su podobne onima koji su neophodne za započinjanje nove runde uzgoja u sustavu.
wherein said HDAC inhibitor is: and wherein said pharmaceutical composition is an aqueous liquid. 
(c) vode; pri čemu je spomenuti HDAC inhibitor: i pri čemu spomenuti farmaceutski sastav je vodena tekućina.
subsequently adding a basic amino acid selected from arginine and lysine until total dispersion, and 
naknadnog dodavanja bazične aminokiseline do potpunog dispergiranja, i
a polypeptide comprising the amino acid sequence of the sushi domain of the IL-15Ra or derivatives thereof. The immunocytokine of claim 1, wherein 
polipeptid, koji sadrži aminokiselinski slijed sushi domene IL-15Ra, gdje konjugat ima aminokiselinski slijed SEQ ID NO: 17.
is hydrogen, halogen, or C1-C6 alkyl wherein said C1-C6 alkyl is substituted with 0-6 halogen and wherein up to two non-adjacent CH2 units of said C1-C6 alkyl may be replaced with —O—; and 
R' je vodik, halogen ili skupina C;-Cx alkil, pri čemu je navedena skupina C,-C4 alkil supstituirana s 0-6 halogena 1 pri čemu do dvije CH? jedinice navedene skupine Ci-C4 alkil koje nisu susjedne, mogu biti zamijenjene s -O-; i
The coupled container 1100 may then be inserted into the recess well 300 of blender base 100 . 
Posuda 1100 može zatim biti umetnuta u spremnik 300 postolja mješalice mješalice 100.
The peptide according to any one of claims 1 to 4 for use according to claim 13 or 14, wherein said vaccine furthermore comprises at least one additional peptide selected from SEQ ID No 1 to SEQ ID No 9, and SEQ ID No 11 to SEQ ID No 26. A kit comprising a container containing a pharmaceutical composition containing the peptide according to any one of claims 1 to 4 or the activated cytotoxic T lymphocyte according to claim 11, in solution or in lyophilized form. 
Antitijelo koje je specifično za peptid MHC/peptidni kompleks MHC-a s peptidom odabranim iz grupe koja se sastoji od SEQ ID br. 4 i 5. Komplet koji sadrži: posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, nukleinskom kiselinom ili vektorom ekspresije u skladu s patentnim zahtjevom 5, stanicom u skladu s patentnim zahtjevom 7 ili aktiviranim citotoksičnim T limfocitom u skladu s patentnim zahtjevom 10, u otopini ili u liofiliziranom obliku;
The compound of claim 1 wherein R3 is one to two substituents independently selected from the group consisting of C1-6alkyl, halogen, and aryl; wherein aryl is optionally substituted with one to three substituents independently selected from the group consisting of halogen, carboxy, aminocarbonyl, C1-3alkylsulfonylamino, cyano, hydroxy, amino, C1-3alkylamino, and (C1-3alkyl)2amino. 
Spoj prema zahtjevu 1 naznačen time da R3 je jedan do dva supstituenta nezavisno izabrana iz skupine koju čine C1-6alkil, halogen, i aril; pri čemu aril je proizvoljno supstituiran s jednim do tri supstituenta nezavisno izabrana iz skupine koju čine halogen, karboksi, aminokarbonil, C1-3alkilsulfonilamino, cijano, hidroksi, amino, C1-3alkilamino, i (C1-3alkil)2amino.
Example diseases include disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea. 
Spoj u skladu s bilo kojim zahtjevom 1 do 11, naznačen time, da se koristi u postupku liječenja poremećaja središnjeg Živčanog sustava; oštećenja središnjeg Živčanog sustava; = kardiovaskularnog poremećaja; gastrointestinalnog poremećaja; dijabetesa insipidusa ili apneje spavanja.
The fluorescent conjugate or composition of the invention and as described in any of the preceding paragraphs may be used for the detection of tumour cells or tumour tissue, such as the detection of the foci of a tumour and/or determination of their location(s), as well as at a resection margin of a tumour from a patient during or after surgical resection of a patient, wherein the patient has colorectal, gastric, biliary, pancreatic, oesophageal, ovarian, breast, prostrate, liver or lung cancer. 
Konjugat prema zahtjevu 1 do 8 ili pripravak prema zahtjevu 9 naznačen time da se koristi pri (a) detekciji žarišta tumora koji eksprimira tumorski marker ili za određivanje položaja tumora koji eksprimira tumorski marker u pacijenta, i/ili (b) otkrivanju tumorskih stanica ili tumorskog tkiva na margini resekcije u pacijentu koji se podvrgava, ili koji je podvrgnut kirurškom zahvatu resekata tumora koji ispoljava tumorski marker .
A reaction mixture comprising a direct buffer and a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR), and wherein the direct buffer comprises 10-50 mM Tris-HCl (pH 8.3), 30-80 mM KCl, 1.4-2.4 mM MgCl2, 0.01%-0.04% Sodium azide, 3%-8% glycerol, 100-350 uM of each dNTPs, 0.2%-0.9% polysorbate 20, 1200-3000 ug/ml BSA, and 0.10-0.35 U/ul of DNA polymerase. 
Reakcijska mješavina koja sadrži izravni pufer, krv na papiru ili bukalni obrisak na papiru 1 više parova početnica, naznačena time, da papir sadrži reagent za lizu, 1 pri čemu neposredni pufer sadrži 10-50 mM Tris-HCI (pH 8.3), 30-80 mM KC], 1,4-2,4 mM MgCI2, 0,01% natrijevog azida -0.04%, 3% -8% glicerola, 100-350 uM svakog dNTP, 0,2% -0,9% polisorbata 20, 1200 do 3000 ug/ml BSA, 1 0,10-0,35 U/ul DNA polimeraze.
The human monoclonal antibody of embodiment 1, wherein said antibody is selected from the group consisting of: the monoclonal antibody CHIR-12.12; 
Monoklonalno antitijelo prema zahtjevu 1, gdje je navedeno antitijelo monoklonalno antitijelo koje sadrži aminokiselinsku sekvencu odabranu iz grupe koja se sastoji od:
The combined organic layer were washed with 10% sodium bicarbonate solution (500ml), water, brine and dried. 
Skupljeni se organski slojevi isperu s 10 % otopinom natrijeva bikarbonata (500 mL), vodom i zasićenom otopinom NaCi, te osuše.
Said perturbation of the magnetic field, which is due to the local lacking of magnetic material, manifests itself in a bending of the field lines, which, in turn, are able to correspondingly orient magnetic particles in a wet coating composition on a printed item, when this latter is brought into sufficient proximity of the device, e.g. 
Navedena se perturbacija magnetskog polja, koja je posljedica lokalnog pomanjkanja magnetskog materijala, manifestira savijanjem silnica polja, koje, sa svoje strane, uzrokuje analogno usmjeravanje magnetskih čestica u vlažnoj smjesi za premazivanje na otisnutom predmetu kada se taj predmet primakne dovoljno blizu navedenog uređaja, npr.
Ophthalmic preparation according to claim 1, wherein BDNF ranges from 15 to 200 µg/µl. 
Oftalmološki pripravak prema patentnom zahtjevu 1, naznačen time da je BDNF u rasponu od 15 do 200 15 µg/µL.
The second cup-shaped body portion 140 has a first aperture 142 provided in the enlarged head 141, as well as a second aperture 147 provided in the bottom 148 thereof, which enables the cavity of the second cup-shaped body portion 140 to communicate with the head 139 of the first cup-shaped body portion 130; the piercing device for the capsule 200, which is also part of the brewing unit and is illustrated in an overturned state in FIG. 3 so as to make the construction details thereof more conspicuous, consists of a disk 170 comprising: 
Drugi trup u obliku šalice 140 ima prvi otvor 142, koji se nalazi na povećanoj glavi 141, kao i drugi otvor 147, koji se nalazi na dnu 148, što omogućuje komuniciranje šupljine drugog trupa u obliku šalice 140 s glavom 139 prvog trupa u obliku šalice 130; uređaj za probadanje za a kapsula 200, koji je također dio jedinice za kuhanje i prikazan ke preokrenutom stanju na -
A method according to any preceding claim wherein the sheet-form material comprises a thermosetting material, the method including the step of causing or allowing the material to cure. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da pločasti materijal za oblikovanje obuhvaća materijal koji se toplinski stvrdnjava, pri čemu postupak uključuje korak u kojem se uzrokuje stvrdnjavanje materijala ili se dopušta materijalu da se stvrdne.
The appropriate substituted benzophenone starting materials for Examples 8-14 were prepared as shown below for 4-trifluoromethyl-benzophenone: 4-Trifluoromethyl-benzophenone 
Odgovarajući benzofenonski (supstituirani) polazni materijali iz primjera 8-14 napravljeni su kao što je prikazano niže za 4-trifluorometil-benzofenon:
Embodiments of the present invention include those compounds wherein R1 is selected from the group consisting of phenyl(C1-3)alkyl, pyridinyl(C1-3)alkyl, and furanyl(C1-3)alkyl; wherein phenyl, pyridinyl, and furanyl are optionally substituted with one to three R11 substituents independently selected from the group consisting of C1-3alkoxy; tetrazolyl, C3-6cycloalkylaminocarbonyl; hydroxy(C1-4)alkylaminocarbonyl; C6-10arylaminocarbonyl wherein C6-10aryl is optionally substituted with carboxy or C1-4alkoxycarbonyl; morpholin-4-ylcarbonyl; chloro; fluoro; trifluoromethoxy; C1-4alkoxycarbonyl; and carboxy; provided that that no more than one R11is C6-10arylaminocarbonyl. 
Spoj prema zahtjevu 1 naznačen time da R' je izabran iz skupine koju čine feniK(C,3)alkil, piridiniKC,;)alkil, i furani(C,;)alkil; pri čemu fenil, piridinil, i furanil su proizvoljno supstituirani sa jednim do tri R!! supstituenta nezavisno izabrana iz skupine koju čine C,;alkoksi; tetrazolil, C,scikloalkilaminokarbonil; hidroksi(C1.4) alkilaminokarbonil:; Cgsoarilaminokarbonil pri čemu CÂ«,oaril je proizvoljno supstituiran sa karboksi ili Ci4alkoksikarbonilom; morfolin-4-ilkarbonil; kloro; fluoro; trifluorometoksi; Ciaalkoksikarbonil; i karboksi; uz uvjet da ne više od jedan R" je C4.,oarilaminokarbonil.
The peptide according to claim 1 or 2, wherein said peptide includes non-peptide bonds. 
peptida u skladu s a), pri čemu navedeni peptid uključuje nepeptidne veze, i
The antibody or antigen-binding fragment according to claim 4, wherein the antibody or antigen-binding fragment cross-reacts with cynomolgus monkey angiopoietin-like protein 4 and rhesus monkey angiopoietin-like protein 4. 
Protutijelo ili fragment koji veže antigen u skladu s patentnim zahtjevom 4, naznačen time, da protutijelo ili fragment koji veže antigen unakrsno reagira s proteinom 4 nalik angiopoietinu cynomolgus majmuna i proteinom 4 nalik angiopoietinu rezus majmuna.
The composition for use according to any one of the preceding claims, wherein the organic solvent has a boiling point of below 100 °C, and preferably below 80 °C. 
Pripravak za primjenu prema bilo kojem od prethodnih zahtjeva, naznačen time, što organsko otapalo ima vrelište ispod 100 "€, a poželjno ispod 80 *C.
a heater to heat the waste in the chamber; 
- > grijač za zagrijavanje otpada u komori;
In addition, cannabinoid receptors regulate the Fc epsilon receptor and chemokine induced degranulation of mast cells and basophils. 
Pored toga, kanabinoid receptori reguliraju Fc epsilon receptor i kemokinom induciranu degranulaciju stanica mastocita i bazofila.
FIG. 4 shows numerous alternative groups that may be used for the R7COO group at the 10-a-position of generalized formula G. As would be appreciated by the ordinarily skilled person, these acylations may be performed for example by substituting the appropriate carboxylic acid R7COOH, carboxylic acid halide R7COX or carboxyl anhydride R7COOCOR7 in the above procedures. 
Slika 4 prikazuje brojne alternativne skupine koje se mogu koristiti za R;COO skupinu kod 10-a-položaja opće formule G. Kao što prosječan stručnjak područja može razumjeti, ove acilacije se mogu izvesti, na primjer, supstituiranjem s prikladnom karboksilnom kiselinom R;COOH, halogenidom karboksilne kiseline R;COO ili karboksilnim anhidridom R;COOCOR; u gornjem postupku.
preparing the inner non-effervescent material comprising at least a colouring and a solid carrier material, wherein the non-effervescent material is a free-flowing powder, wherein the non-effervescent material does not effervesce on contact with water; 
(i) - pripremanje unutarnjeg ne-pjenušavog materijala koji sadrži barem boju i kruti materijal nosača, pri čemu je ne-pjenušavi materijal prah koji slobodno teče, pri čemu se ne-pjenušavi materijal ne pjenuša u kontaktu s vodom;
Although, there are no such specifications set for ammonia caramel, in general it will have an A280/560of less than 80, more specifically of less than 50. 
Tako nisu postavljene takve specifikacije za amonij karamelu, općenito ona će imati A2g0/s6o manji od 80, specifičnije manji od 50.
A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 14 i farmaceutski prihvatljiv nosač.
Freight container according to any one of the preceding claims, comprising a battery (9) for feeding the air conditioning unit (7) and/or starting the generator, wherein the battery is arranged to be charged by the generator, preferably wherein the fuel tank (20) comprises an L-shape and the battery (9) is accommodated in a cavity formed by said L-shape. 
Teretni kontejner sukladno bilo kojem od prethodnih patentnih zahtjeva, sadrži bateriju (9) za dovođenje jedinice (7) za klimatiziranje zraka i/ili pokretanje generatora, ta baterija se postavlja na način da puni generator, poželjno Pri tome spremnik (20) za gorivo sadrži L-oblik, 1 baterija (9) se smješta u šupljinu oblikovanu putem L-oblika.
Modular antibody according to claim 8, which contains a binding site specifically binding to Her2 and contains an amino acid sequence selected from the group consisting of Sequ. 
Modularno antitijelo prema patentnom zahtjevu 8, gdje je protein fuzioniran za modularno antitijelo odabran iz grupe koja se sastoji od drugih modularnih antitijela, imunoglobulina, laganada, proteina skele (“scaffold”), enzima, i toksina.
at least one pump placed in the fluid circuit, optionally placed between the collecting unit and the heat exchange unit. 
najmanje jednu crpku koja se nalazi u fluidnom krugu (37), koja se može nalaziti između sabirne jedinice (35) i jedinice za izmjenu topline.